NCT06613009 - Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer | Biotech Hunter

Enrollment

190

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

August 30, 2027

Study Completion Date

August 30, 2027

Conditions

Small Cell Lung Cancer

Interventions

DRUG

IBI3009

Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3009)

Trial Locations (10)

2145

RECRUITING

Westmead Hospital, Westmead

2500

NOT_YET_RECRUITING

Wollongong Hospital, Wollongong

3084

RECRUITING

Austin Hospital, Heidelberg

230022

NOT_YET_RECRUITING

The First Affiliated Hospital of Anhui Medical University, Hefei

250117

NOT_YET_RECRUITING

Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital), Jinan

310005

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

330006

NOT_YET_RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

350005

NOT_YET_RECRUITING

The First Affiliated Hospital of Fujian Medical University, Fuzhou

410000

RECRUITING

Hunan Cancer Hospital, Changsha

450000

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY